A Study of Epoetin Beta (NeoRecormon) in Predialysis Patients With Renal Anemia
Status:
Completed
Trial end date:
2006-07-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the tolerability, and effect on quality of life, in patients
receiving multi-dose NeoRecormon administered by RecoPen in predialysis patients with chronic
renal anemia. The anticipated time on study treatment is 10 months, and the target sample
size is 60 individuals.